Magnesium isoglycyrrhizinate alleviates alcohol-associated liver disease through targeting HSD11B1
eLife · 2026
DOI: 10.7554/elife.109174 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2026. Verfasst von Lu Xiao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Medicine Research Institute and Department of Anesthesiology, The First Affiliated Hospital of Jinan University, Guangzhou, China. Hauptthemen laut MEDLINE: Triterpenes, Saponins, 11-beta-Hydroxysteroid Dehydrogenase Type 1, Liver Diseases, Alcoholic. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Projects in Guangzhou, The Sixth Affiliated Hospital of Jinan University.
Abstract (Originalsprache)
While magnesium isoglycyrrhizinate (MgIG) is a clinically approved therapy for alcohol-associated liver disease (ALD), its precise molecular targets and mechanisms remain uncharacterized. This study aimed to define MgIG’s hepatoprotective actions in chronic-binge ALD mouse models and ethanol/palmitic acid-exposed AML-12 hepatocytes. Through an integrated strategy encompassing RNA sequencing, molecular docking, and microscale thermophoresis, we discovered that MgIG directly binds to hydroxysteroid 11-beta dehydrogenase 1 (HSD11B1) at residue 187, a finding corroborated by molecular dynamics simulations. In vivo, MgIG markedly attenuated alcohol-induced liver injury, evidenced by ameliorated histological damage, reduced hepatic steatosis, and normalized liver-to-body weight ratios. In vitro, it effectively reduced lipid accumulation, inflammation, and apoptosis. Mechanistically, RNA sequencing identified isopentenyl diphosphate delta isomerase 1 (IDI1) as a key downstream effector. Hepatocyte-specific genetic manipulations confirmed that MgIG modulates the SREBP2–IDI1 axis, thereby suppressing lipogenesis, inflammatory responses, and apoptotic pathways. We reveal HSD11B1 as a novel direct molecular target of MgIG and elucidate its therapeutic mechanism through the HSD11B1–SREBP2–IDI1 signaling axis, which profoundly impacts ALD pathogenesis. These findings not only validate MgIG’s clinical utility but also highlight a promising new therapeutic target for ALD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Medicine Research Institute and Department of Anesthesiology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
- Department of Gastroenterology, People's Hospital of Guangming District, Shenzhen, China.
- Department of Gastroenterology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
- Department of Systems Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen, China.
- Southern Medical University Shenzhen Hospital, Shenzhen, China.
- Department of Interventional Radiology and Vascular Surgery, The Sixth Affiliated Hospital of Jinan University, Dongguan, China.
Förderung
- National Natural Science Foundation of China
- Science and Technology Projects in Guangzhou
- The Sixth Affiliated Hospital of Jinan University
Zitieren
APA
Xiao, L., Li, L., Wu, S., Che, Z., Du, Y., Zheng, J., Yan, J., Wang, H., Zhang, H., Li, Y., & Xiao, J. (2026). Magnesium isoglycyrrhizinate alleviates alcohol-associated liver disease through targeting HSD11B1. eLife. https://doi.org/10.7554/elife.109174
Vancouver
Xiao L, Li L, Wu S, Che Z, Du Y, Zheng J, et al. Magnesium isoglycyrrhizinate alleviates alcohol-associated liver disease through targeting HSD11B1. eLife. 2026. doi:10.7554/elife.109174
BibTeX
@article{Xiao2026,
author = {Xiao, Lu and Li, Lu and Wu, Shasha and Che, Zhaoyi and Du, Yuyang and Zheng, Jingyi and Yan, Jingsong and Wang, Hao and Zhang, Hong and Li, Yan and Xiao, Jia},
title = {Magnesium isoglycyrrhizinate alleviates alcohol-associated liver disease through targeting HSD11B1},
journal = {eLife},
year = {2026},
doi = {10.7554/elife.109174}
}
EUVIMED